Therapeutic approaches to allergic rhinitis: Treating the child

Abstract

Allergic rhinitis is currently the most common of all chronic diseases in children. However, children frequently lack the ability to verbalize their symptoms, with the result that the condition may go undiagnosed and untreated. Unfortunately, untreated allergic rhinitis not only detrimentally affects children’s physical and psychosocial well-being, quality of life, and capacity to function and learn, but it is also associated with and may contribute to potentially serious sequelae, including asthma, sinusitis, and otitis media. Because children may not accurately describe their symptoms, the classic signs of allergic rhinitis in the pediatric population, including the allergic shiner, the allergic crease, and the allergic salute, are particularly important in enabling the clinician to recognize those children who may have this condition; other significant signs include mouth breathing, snoring, chronic cough, and continual throat clearing. The options for treating allergic rhinitis in the child are the same as those for the adult, and the clinician can expect the same level of efficacy. Environmental control for allergen avoidance is an important goal, but the clinician must prescribe it within the context of the family’s lifestyle to obtain compliance. Complete avoidance of inhalant allergens is not always feasible, and medications are necessary. Oral antihistamines remain the mainstay of initial treatment for allergies. Given evidence of the significant deleterious effects of the sedating antihistamines on learning, the clinician should prescribe nonsedating second-generation agents whenever possible. Decongestants may be needed. Intranasal corticosteroids are a most effective option, and these agents lack the systemic side effects associated with orally administered steroids. In persistent disease, allergen immunotherapy injections may be considered. In all cases, the clinician should consider issues that are likely to influence compliance in the pediatric population. (J Allergy Clin Immunol 2000;105:S616-21.)